Nomination Committee for Elicera therapeutics appointed
Gothenburg, October 31, 2023 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation immuno-oncological treatments based on CAR T-cells and oncolytic viruses armed with the company’s commercially available iTANK-platform, announces that representatives of the largest owners have appointed the nomination committee ahead of the Annual General Meeting 2024. On May 10, the Annual General Meeting established rules to guide the work of the Nomination Committee. The three largest owners on September 30, 2023, were Magnus Essand, Di Yu